Article Details

Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with ...

Retrieved on: 2019-07-14 20:00:00

Tags for this article:

Click the tags to see associated articles and topics

Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with .... View article details on hiswai:

Excerpt

<div>The company has received funding from institutional investors, including <b>Lightspeed Venture Partners</b> and Sutter Hill Ventures. For more information ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up